Aptose Biosciences Inc.

AI Score

0

Unlock

0.21
0.01 (3.45%)
At close: Jan 15, 2025, 12:49 PM
undefined%
Bid 0.2
Market Cap 12.36M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.92
PE Ratio (ttm) -0.07
Forward PE n/a
Analyst Buy
Ask 0.21
Volume 387,340
Avg. Volume (20D) 6,791,393
Open 0.20
Previous Close 0.20
Day's Range 0.20 - 0.21
52-Week Range 0.13 - 2.30
Beta undefined

About APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Ph...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 16, 1992
Employees 35
Stock Exchange NASDAQ
Ticker Symbol APTO

Analyst Forecast

According to 3 analyst ratings, the average rating for APTO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 2335.46% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
3 weeks ago · Source
-4.81%
Aptose Biosciences shares are trading higher after... Unlock content with Pro Subscription
1 month ago · Source
-3.05%
Aptose Biosciences shares are trading lower after the company announced the pricing of an $8M public offering.